At UBC, I work in a program that helps patients breathe easier — literally. If at any time we can get medication to a patient one day sooner, that’s one more day they can breathe easier.
risk evaluation mitigation strategy
DIA’s slogan, “It’s a Meeting of the Minds” perfectly sums up this banner event for the pharmaceutical and biotech industry. Next week, influential leaders and innovators in life sciences will gather in Washington, D.C., to discuss hot topics, network and learn. We’ll be in the mix and can’t wait to meet, share what’s top of mind, and give you something to munch on.
Creating a REMS assessment report requires a high-functioning, coordinated team effort, often involving numerous departments and external vendors. UBC’s REMS experts have designed, implemented, and/or evaluated more than 100 RiskMAPS and REMS programs for drugs to treat everything from diabetes to organ transplant rejection.
FDA mandated Risk Evaluation and Mitigation Strategies (REMS) are often viewed as obstacles to product access. Having supported more than 100 REMS programs, UBC has a different perspective. We view REMS programs as paths to prescriber loyalty and commercial success.
Click here to access our free whitepaper “100 REMS Programs and Counting – Top Lessons Learned,” by leading industry expert, Annette Stemhagen, DrPH, FISPE, Senior Vice President, Safety, Epidemiology, Registries, and Risk Management.